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The epithelial to mesenchymal transition (EMT) is implicated in many processes, ranging from tissue and
organogenesis to cancer and metastatic spread. Understanding the key regulatory mechanisms and mediators
within this process offers the opportunity to develop novel therapeutics with broad clinical applicability. To date,
several components of EMT already are targeted using pharmacologic agents in fibrosis and cancer. As our
knowledge of EMT continues to grow, the potential for novel therapeutics will also increase. This review focuses on
the role of EMT both as a necessary part of development and a key player in disease progression, specifically the
similarity in pathways used during both processes as targets for drug development. Also, the key role of the tumor
microenvironment with EMT is outlined, focusing on both co-factors and cell types with the ability to modulate the
progression of EMT in cancer and metastatic disease. Lastly, we discuss the current status of clinical therapies both
in development and those progressed to clinical trial specifically targeting pathologic EMTs including small molecule
inhibitors, non-coding RNAs, exogenous co-factors, and adjunctive therapies to current chemotherapeutics.
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The epithelial to mesenchymal transition (EMT) was
first described in the context of being a fundamental
component in the differentiation of tissues and organs
within the developing embryo [1]. Beyond tissue and or-
ganogenesis, EMT has been described as a crucial medi-
ator of wound healing, a feature of EMT necessary for
tissue remodeling post-injury [2]. The characteristics of
EMT that are essential to wound healing also connect
EMT to organ fibrosis, including pulmonary fibrosis,
renal fibrosis, and hepatic fibrosis. In these settings,
EMT is intimately linked to diseased states. The integral
role of EMT in disease was taken one step further with
evidence supporting a key role in tumor initiation and,
subsequently, the progression of metastatic disease [3].
EMT is contemporarily classified into 3 classes: type 1
referring to embryogenesis; type 2 referring to wound heal-
ing; type 3 referring to its role in cancer and metastases. A
hallmark of each is the process through which epithelial
cells lose their cell-cell junctions, apical-basal polarity, and
re-organize their cytoskeleton by e-configuring their gene* Correspondence: ankothari@lumc.edu
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setting of type 1 and 2 EMT. In type 3 EMT, dysregulation
leads to diseased states [4].
On a molecular level, EMT is defined by several inter-
mediates responsible for influencing gene expression.
These include transcription factors, multiple interacting
signal pathways, promoter sequence modifications, and
autocrine signaling. Of these, the principal regulators of
EMT are transcription factors classified into 3 families:
SNAIL, TWIST, and zinc-finger E-box-binding (ZEB). The
fundamental event in EMT is the repression of epithelial
cadherin (E-cadherin), which is responsible for maintaining
adherens junctions and cell-cell adhesion. SNAIL, TWIST,
and ZEB factors all can repress E-cadherin while also
activating key mesenchymal genes including N-cadherin
(cell-cell adhesion), vimentin (an intermediate filament
protein that regulates cell motility), and fibronectin 1
(cell growth and migration). Together, these transcription
factors orchestrate the activation of mesenchymal gene ex-
pression while repressing epithelial genes through diverse
downstream targets.
The same mediators used for modifying gene expres-
sion are used as biomarkers to identify a cell as epithelial
or mesenchymal. For example, expression of E-cadherinan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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whereas expression of N-cadherin, vimentin, and/or
fibronectin 1 are used to describe the mesenchymal
phenotype (see Figure 1). The importance and clinical
relevance of these pathways and mediators will be dis-
cussed throughout this review [5].
The focus of this review will be on 3 major areas. First,
the role of EMT as a necessary pathway to development
and healing. Next, the pathophysiologic impact of EMT on
diseased states (primarily fibrotic phenotypes and cancer).
Finally, discussing the areas within the spectrum of EMT
which allow for novel therapeutics and the current progress
towards clinical application.
Review
SECTION 1: The role of EMT in development and diseased
states
EMT and development
EMTs are pathways followed during normal development;
most organs and adult tissues are generated via these tran-
sitions embryologically. Each of these transitions rely on
signal cascades with multiple regulatory and feedback loops
allowing both plasticity and cooperation during develop-
ment. EMT plays a prominent role during gastrulation and
many of the key molecular players during these processes
have been noted to be important in disease progression
during adulthood. For example, members of the TGFβ
superfamily are powerful inductors of gastrulation [6].
SNAIL1 and SNAIL2, known mediators of EMT in adults,
are dependent on TGFβ activation and required for gastru-
lation to proceed [7,8].Figure 1 Schematic of EMT, EMT inducers, and potential or existing aThe importance of key EMT mediators in early gastrula-
tion is further emphasized in SNAIL-mutant mice where
cells are unable to migrate from the primitive streak,
effectively halting development [9]. TGFβ signaling
and the SNAIL family of transcription factors are two
important influences during dysregulated EMT in adult
disease, as well. Understanding the signaling targets dur-
ing embryologic EMTand comparing them to those found
in the progression of disease is an area of research that
may offer new therapeutic targets.
EMT and diseased states
EMT has a role in several disease states including
pathologic organ degradation (ie fibrosis) and cancer.
How EMT fits into these processes will be reviewed,
including the initiating signal pathways, downstream
targets, and mechanisms for regulating these pathologic
EMTs.
In all pathologic EMTs, a series of steps are conserved
and are crucial for defining an epithelial cell’s conversion
to a mesenchymal phenotype. Epithelial cells are broadly
characterized as those positioned on the basement mem-
brane (either as single layered or multilayered tissues),
show polarity, adhere, and communicate using cell-cell
junctions [10]. Loss of these characteristics places epithelial
cells on a spectrum. On one end is the epithelial phenotype
and on the other end is the mesenchymal phenotype.
At the furthest extreme, the mesenchymal phenotype,
the result is cells which are invasive and resistant to
apoptosis [11]. These features of EMT are consistent be-
tween cell types and tissue environments.reas within the framework for therapeutic intervention.
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ing cell-cell junctions and their dissolution during EMT.
Cell-cell junctions are critical for maintaining basement
membranes and the integrity of epithelial layers. In verte-
bral cells, tight junctions, gap junctions, and desmosomes
are the primary regulators of these connections [11,12].
Several EMT activators act either jointly or independently
on each of these cell contact mediators and their impact
on cell-cell junctions is nearly the same regardless of cell
type [5]. The importance of factors on the cell surface to
EMT is further illustrated by recent findings illustrating
that alterations in the glycosylation of cell surface glycopro-
teins impacts cellular adhesive properties. The characteris-
tics of altered O- and N-glycans through mRNA expression
during tumor progression is extremely relevant and well
described in a recent review [13].
EMT and organ fibrosis Fibrotic tissues are characterized
by an up-regulation of extracellular matrix (ECM) protein
deposition eventually leading to compromise of organ func-
tion, and in the most severe cases, organ failure [14]. The
cells responsible for ECM protein deposition are myofibro-
blasts typically in response to epithelial or endothelial injury
[15]. As tissue repair progresses, the role of myofibroblasts
shifts from creating a scaffold for healing into facilitating
wound contraction and closure [16]. Myofibroblasts origin-
ate from several cell types most notably existing epithelial
cells, endothelial cells, interstitial fibroblasts, and myeloid
precursor cells in bone marrow [17-20].
Inflammatory cytokines, specifically TGFβ and IL-1,
are critical in the differentiation of cells from any site
into myofibroblasts [21]. In wound healing, myofibro-
blasts are key to creating wound tension and depositing
important co-factors required for wound contraction.
This process is tightly regulated, and at its completion,
the population of myofibroblasts recruited to the site of
injury to promote healing undergoes population-wide
apoptosis [22]. In situations where myofibroblasts persist
in the extracellular matrix, a fibrotic phenotype develops.
In wounds, this is manifested as hypertrophic scar or keloid
[23]. In organs, the result is fibrosis [24,25].
Alveolar epithelial cells, hepatocytes, lens epithelium,
endothelial cells, mesothelial cells, and cardiomyocytes
all have the potential to undergo EMT and resemble
myofibroblasts, subsequently contributing to organ fi-
brosis [26]. In pulmonary fibrosis models, TGFβ stimu-
lates EMT in alveolar epithelial cells. Similarly, CCL4-
induced liver fibrosis is linked to EMT in hepatocytes.
Recent evidence shows a role for EMT in peritoneal
fibrosis in patients that receive peritoneal dialysis in a
MAPK and SNAIL1 dependent fashion [27]. EMT in
lens epithelial cells causes progressive capsular opacifi-
cation and can be prevented by inhibiting TGFβ with
Smad7 [26].In renal fibrosis, mice that do not express Smad3
(a target of TGFβ) are protected from development of fi-
brosis. The crucial role of TGFβ in renal fibrosis was taken
a step further by Zeisberg et al. who demonstrated that
inhibiting TGFβ with an antagonist (BMP7) actually could
revert renal fibrosis in mice [28].
EMT and cancer The pathologic potential of EMT is seen
in organ fibrosis and similar mechanisms are seen in the
development of cancer, evolution of disease, and meta-
static progression. In cancer, EMTs rely on: 1) exogenous
induction agents acting through transcriptional control 2)
Non-coding RNAs and 3) creating and maintaining cancer
stem cells [29].
1. Transcriptional control mechanisms
The discovery of the transcription factor SNAIL1
interacting with the CDH1 promoter to repress the pro-
duction of E-cadherin began our understanding of how
EMT is regulated [30,31]. Numerous other transcription
factors have been found to play a role in the progression
of epithelial cells to a mesenchymal phenotype including
SNAIL2, ZEB1, ZEB2, E47, KLF8, TWIST1, and FOXC2,
all which have the ability to promote EMT in various cell
cancer lines [32,33]. Of these, the nuclear factors which
seem to be most important are SNAIL, ZEB, and
TWIST proteins and these can be modulated to initiate
EMT by exogenous stimuli including hypoxia, bile
acids, and nicotine [34-36].
The association between disease progression and solid
tumor oxygenation is seen in various malignancies. It is
apparent that tumor hypoxia contributes to several
features of aggressive cancers by enhancing invasive
growth, local spread, and distant deposits [37]. The
mechanism for hypoxic influence of these features is
likely multifactorial, however there is clear interplay with
EMT. In pancreatic tumor cells, hypoxia (induced by
culturing cells in a hypoxic chamber) resulted in expres-
sion of EMT makers when compared to normal condi-
tions [34]. This observation is seen in other solid tumors
including lung and breast [38].
Cholestatic disorders seem to promote hepatic fibrosis
and to the progression of carcinogenesis in cholangio-
cytes and hepatocytes. Studies have shown that chendeo-
cycholic acid (CDCA), a bile acid, can activate EGFR to
mediate gene expression. In a cDNA microarray, CDCA
increased the expression of SNAIL to repress E-cadherin
both in vitro and in vivo in liver cancer models, initiat-
ing an EMT program [36]. The ability for bile acids to
play an activating role is just one of many examples
where exogenous substrates can induce EMT.
Another substrate which activates EMT through a simi-
lar mechanism is nicotine. Specifically, in breast and lung
cancer cell lines (A549, MDA-MB-468, MCF-7), treatment
with nicotine increased the proliferation, invasion, and
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dose-dependent fashion. Notably, expression of E-
cadherin was repressed while the expression of fibro-
nectin and vimentin, both mesenchymal markers, in-
creased. The mechanism for these changes occurred
through signaling by nicotinic acetylcholine receptors
(nAChRs) [35].
Recent data demonstrates a pathway for cigarette smoke
to stimulate EMT in small bronchi of patients demonstrat-
ing a mechanism contributing to the progression of dis-
ease. In primary human bronchial epithelial cells (HBEC),
exposure to cigarette smoke led to expression of EMT
markers by increased production of intracellular ROS, re-
lease of TGFβ, and TGFβ activation of the transcription
factors Smad3 and ERK1/2 [39]. This kind of interaction
between an exogenous substrate and the cellular machin-
ery activating EMT has significant clinical implication as
treatments can be designed to potentially halt or reverse
the progression of disease.
2. Non-coding RNAs
Non-coding RNAs and, in particular, microRNAs
(miRNAs) have gained significant attention for their
ability to modify gene expression allowing for quick cel-
lular adaptation to new environments and conditions
[29,40]. The regulatory association of miRNAs is seen
in many settings including development, maintaining
cell homeostasis, and cell-cell interaction [41]. Li et al.,
in 2009, showed a role for miRNAs in reversing EMT
in pancreatic tumor cells that were resistant to com-
mon chemotherapeutics [42].
Since that time, numerous miRNAs have been found
to interact either directly or indirectly with EMT ma-
chinery in several cell models [43]. Interestingly, these
miRNAs can act as either tumor suppressors or tumor
activators based on the cell type and environment they
interact with. Additionally, their adaptive properties play
a role in chemotherapy resistance.
Two major classes of miRNAs have been studied exten-
sively in the setting of EMT: the miR-200 family and the
miR-34 family. Other families include the miR-205, miR-9,
and miR-10 families, respectively. The miR-200 family
has five named members located on human chromo-
some 1 (mir-200a, mir-200b, mir-429) and 12 (mir-200c,
mir-141). Both the miR-200 and miR-34 families are typic-
ally considered to be “tumor suppressive” as their mem-
bers all stabilize the epithelial phenotype [44].
The interplay between miR-200 and the ZEB family of
transcription factors to maintain E-cadherin expression
has been validated in several systems. In a TGFβ-induced
model of EMT in a murine mammary cell line, miR-200
family member expression was repressed. This same cell
line was transfected with synthetic pre-miRNAs to stimu-
late overexpression of corresponding miR-200 members
in vitro. The result was inhibiting EMT in the transfectedcell lines, when compared to control, by increasing the ex-
pression of E-cadherin. Furthermore, using an elegantly de-
signed luciferase assay, miR-200 family members were
noted to interact directly with the transcription factors
ZEB1 and ZEB2 [45]. ZEB1 and ZEB2 typically act as EMT
inducers by suppressing E-cadherin expression, however in
the presence of miR-200, ZEB1 and ZEB2 could not
interact with E-cadherin and the epithelial phenotype
was maintained [45,46].
The clinical relevance of miR-200 family members can
be seen in malignant breast, prostate, and colon cancer
cells. Silencing of the miR-200 family induces early trans-
formation of epithelial cells leading to EMT, reinforcing
the role of these miRNAs in tumor suppression [47].
An interesting link between the p53 tumor suppressor
gene, SNAIL, and the miR-34 was described by Siemans
et al. in 2011. In colon cancer cells, activation of p53 not-
ably induced the expression of miR-34 family genes,
resulting in the inhibition of SNAIL activation. As would
be predicted, a correlate decrease in EMT markers was
seen in the absence of SNAIL activation in this cell line.
Treatment of cells with miR-34 halted TGFβ dependent
EMT. It was noted, however, that the action of miR-34
family members was not unidirectional. The miR-34 fam-
ily promoter sequences contain E-boxes which can be
bound by SNAIL, resulting in decreased expression of
miR-34. This double negative feedback loop between miR-
34 and SNAIL offers an interesting regulatory mechanism
for EMT creating unique challenges in drug development
targeting either of these factors [48].
In contrast to the tumor suppressive functions of miR-
200 and miR-34, the miR-9 family appears to be tumor
activating through a direct interaction with the CDH1
promoter which subsequently initiates EMT [49]. miR-9
expression is increased in primary breast, gastric, and
brain cancers [29]. Additionally, increased expression of
miR-9 is seen in metastatic disease further supporting a
tumorigenic role for this family of miRNAs.
It must be emphasized that work with non-coding
RNAs is far from complete and their relevance to cancer
(and cancer therapy) remains imprecise. While the miR-
200 family appears to have compelling data for a tumor
suppressive function, as discussed above, there is are also
data indicating a pro-metastatic niche for miR-200 fam-
ily members.
In samples from colon cancer patients, there is low-
ered expression of miR-200 within the primary tumor
which fits the impression that miR-200 is tumor sup-
pressive. However, in metastatic lesions, miR-200 ex-
pression is high [47,50]. This allows for argument that
miR-200 plays a pro-metastatic role in cancer by stabiliz-
ing the mesenchymal phenotype after deposition to dis-
tant sites (i.e. an important regulatory element in the
mesenchymal to epithelial transition). Other evidence
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atic, breast, and gastric cancer.
Another important miRNA family is the miR-10 group
including miR10b. In the study of metastatic breast can-
cer cells, miR-10b was noted to be highly expressed and
positively regulate cell invasion. It was also able to initi-
ate tumor formation and played a role in distant metas-
tases. Taken together, these properties are highly
suggestive that miR-10b is implicated in EMT [51].
3. Cancer stem cells
The concept of the cancer stem cell is based on the
hypothesis that a single cell type or subset of cells can
act as tumor-initiators in various cancers ranging from
hematopoietic to solid organ. By definition, these cancer
stem cells (CSC) have features which give them “stem-like”
properties allowing for self-renewal and differentiation
leading to the histologic heterogeneity displayed by tu-
mors [52].
Seminal work done in the mid-1990s provided com-
pelling evidence supporting the role of CSCs in tumor
initiation and progression in acute myeloid leukemia
(AML). The AML-initiating cells, defined by their cell
surface marker expression (CD34+,CD38-), were able to
proliferate, disseminate, and maintain an AML phenotype
similar to the patients they were derived from after trans-
plantation into severe combined immune-deficient (SCID)
mice [53].
Furthermore, the AML-initiating cells appeared to be
derived from normal hematopoietic stem cells directly
linking stem cells to tumorigenic cells. In other words,
normal primitive cells underwent leukemic transform-
ation resulting in the first experimentally described
CSC population [54]. This pattern of tumor-initiation
has subsequently been described in various solid tu-
mors including brain, breast, pancreatic, prostate, and
others [55-59].
Ultimately, CSCs exert their pathophysiologic impact
in several ways. Their ability to self-renew and differenti-
ate is at least partly responsible for the heterogeneity
seen within tumors. One potential consequence of this is
chemotherapy and radiotherapy resistance within popula-
tions of tumors. Additionally, CSCs can regenerate a
tumor when transplanted into an appropriate host in ex-
perimental settings. This offers a proposed mechanism for
metastatic disease and cancer recurrence. These proper-
ties have made CSCs, irrespective of their tumor of origin,
extremely important for cancer therapy and an important
new cancer target.
The machinery of EMT appears to connect directly to
the formation and maintenance of CSCs. Mani et al. in-
duced EMT in human, non-tumorigenic mammary epi-
thelial cells using either TWIST or SNAIL transcription
factors. As seen in prior studies, exposed cells acquired a
mesenchymal phenotype [30]. Studying these cells usingflow cytometry revealed a pattern of cell surface expres-
sion that was seen in breast cancer stem cells (CD44High/
CD24Low). EMT made non-tumorigenic epithelial cells, at
least in breast tissue, look like cancer stem cells.
While it was interesting that EMT made epithelial
cells look like stem cells, more important was the dis-
covery that these cells acted like stem cells. CD44High/
CD24Low cells were able to self-renew and give rise to
multiple cell lineages. Furthermore, it was noted that
CD44High/CD24Low cells expressed a mesenchymal pheno-
type and up-regulated the expression of EMT transcrip-
tion factors [60]. Together, these findings connected two
important cancer-related processes – CSCs and EMT.
Other important EMT signaling pathways are also im-
plicated in the transformation and maintenance of CSCs.
For example, Wnt signaling is a well-studied pathway
necessary for a variety of EMTs, both developmental and
pathologic [61]. Wnt signaling is classically described as
being canonical or non-canonical based on the involve-
ment of β-catenin [62]. Hyperactivity of canonical and
non-canonical Wnt pathways can trigger EMT programs
and, more recently, play key roles in CSC biology [61].
In fact, Wnt activity may be used as a marker for de-
fining CSCs in some malignancies. Using colon CSCs de-
rived from patient samples, Wnt signaling was assessed
using a GFP reporter system. Cells with high GFP expres-
sion notably had increased clonogenicity compared to those
cells with low GFP expression. Stated another way, colon
CSCs with high Wnt expression were highly potent at indu-
cing tumors following injection into mice. The extent of
Wnt activation was positively correlated with expression of
well-studied cell surface makers for CSCs [63].
Notch signaling is another important pathway required
for the conversion and maintenance of CSCs using
EMT. Multiples studies show the importance of Notch
signaling in multiple breast cancer subtypes and its role
in invasive disease. Notch signaling, specifically Notch4
receptor activation, is increased in breast CSCs. In
addition, Notch signal pathway inhibition decreases the
number of breast CSCs both in vitro and in vivo [64].
The importance of Notch signaling is also seen in pan-
creatic CSCs. The γ-secretase inhibitor IX can be used
to inactivate Notch signaling. After treating pancreatic
CSCs with this secretase inhibitor, cell proliferation,
migration, and invasion are all decreased. The mechan-
ism for this appears to be through inhibiting the
mesenchymal transition of pancreatic cells lines dem-
onstrating the importance of Notch signaling to EMT
[65]. Treatments directed at Wnt and Notch signal
pathways may allow for regulation of EMT in tumors
and modulation of CSCs.
A property of CSCs with important clinical relevance
is the observation that they demonstrate resistance to
both chemotherapy and radiotherapy [59]. Imatinib
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ment of chronic myeloid leukemia (CML) with excellent
clinical result. Early studies, following its approval for use
by the Food and Drug Administration in 2001, showed a
complete response to therapy in 76% of patients at a me-
dian follow-up of 19 months [66].
However, these results have since been somewhat tem-
pered by the finding that patients with an early response
to imatinib show evidence of disease recurrence [67].
The mechanism for this appears to be supported by a
significant role for CSCs in resisting initial treatment
and leading the progression to cancer recurrence as
CSCs isolated from patients with CML show insensitivity
to imatinib [68]. Some authors describe this as the
“weed” or “dandelion” hypothesis as it may appear the
problem is solved, but until the root is removed the
weed can and will come back [69].
The “dandelion” hypothesis was tested by Li et al. in a
breast cancer model. Cells were taken from patients with
HER2+ breast cancer before and after treatment with
lapatinib. Following chemotherapy, the percentage of
CD44High/CD24Low cells increased. These cells, with a mo-
lecular signature consistent with breast CSCs, were able to
self-renew and had a propensity for tumor formation [70].
CD44High/CD24Low breast CSCs appear to also show resist-
ance to conventional radiation therapies [71]. The impli-
cation of these data are two-fold. First, chemotherapy
and radiotherapy appear to select for the survival CSCs.
Second, chemotherapy and radiotherapy do not impair
the ability of CSCs to grow and replicate.
The focus of this review to this point has been on
EMT, however an important process that must be dis-
cussed is its “opposite” pathway, mesenchymal to epithe-
lial transition (MET). Just as EMT plays a critical role in
development, MET also is a process first recognized in
development. One specific example is the formation of
epithelial nephrons which require the transcription fac-
tor Pax-2 to initiate MET. This illustrates that while
MET functions to transition cells to an epithelial
phenotype, the regulatory factors required are not ne-
cessarily the same for both processes [72]. MET is an
expansive topic and the migrating cancer stem cell
(MCSC) model will be discussed to briefly emphasize
the role MET plays in metastatic disease and distant
seeding of tumor cells.
The (MCSC) model attempts to integrate the concepts
of CSC, EMT, MET, and metastatic disease. CSCs are
generated via an EMT allowing them the ability to mi-
grate and disseminate. Upon reaching a distant site, the
CSC is exposed to a new environment which can either
promote dormancy or undergo a MET to recapture epi-
thelial characteristics. The next step would be the forma-
tion of a metastatic lesion with conserved features from
the primary tumor [73].The relevance to this model on a clinical level cannot
be understated as therapies targeting EMT could inad-
vertently promote MET and progression of disease.
Overcoming these challenges will likely define the next
steps in cancer drug development directed at EMTs.SECTION 2: Targeting EMT and developing novel therapies
Several mechanisms have been proposed to target EMT
to develop novel cancer therapeutics. These targets include
transcriptional regulators (ie SNAIL, TGFβ), non-coding
RNAs, and CSCs. Additionally, a new focus of research
centers on the interactions between the tumor micro-
environment and its role in initiation, propagation, and
termination of EMT. Novel therapeutic targets have
emerged within the tumor microenvironment which
have promising implications for cancer therapy.
As the key players within the epithelial-mesenchymal
transition (EMT) continue to be elucidated, novel cancer
targets are being identified within this framework to direct
future clinical applications. Broadly, these therapeutic tar-
gets can be classified into 2 large categories: (1) preventing
EMT (2) altering the tumor microenvironment.Preventing EMT
Targeting mediators of transcriptional control The
first target for preventing EMT is developing interventions
against very specific intermediates of the transition. Key
players, as discussed, include TGFβ and transcription
factors, and most current clinically-applicable therapies
are based on these targets. TGFβ activity is modulated
with several strategies including small molecule inhibitors
and exogenous compounds.
1. Small molecule inhibitors
TGFβ signaling has classically been targeted using
antisense oligonucleotides, monoclonal antibodies, and
chemical inhibitors for treatment of various inflamma-
tory and neoplastic conditions [74]. Small molecule inhibi-
tors offer a novel approach to modulating the effects of
TGFβ at multiple levels [75].
CX-4945 is a small molecule inhibitor of CK2 (protein
kinase CK2, a serine/threonine kinase) and is the first
orally bioavailable inhibitor in its class. Previously, a link
between CK2 and TGFβ signaling was proposed, specif-
ically by inducing EMT [76]. Treatment of a human lung
adenocarcinoma cell line (A549) with CX-4945 demon-
strated a potent inhibition on the signaling of TGFβ and
down-regulation of EMT markers. CX-4945 inhibited the
TGFβ1 cadherin switch, preventing progression towards a
mesenchymal phenotype by A549 cells. Additionally, CX-
4945 halted TGFβ mediated signaling in both canonical
Smad pathways and non-Smad pathways (Akt and ERK1/
2), Wnt pathways, and focal adhesion pathways (FAK,
Src, MMP, NF-kB) [77].
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the treatment of advanced solid tumors and multiple
myeloma. It has reached phase 2 study for treatment of
non-resectable cholangiocarcinoma in combination with
gemcitabine and cisplatin compared to standard care of
gemcitabine plus cisplatin. The study is presently active
and recruiting patients. CX-4945 is also in phase 1 study
for the treatment of relapsed or refractory multiple
myeloma.
Another group of small molecules targeting TGFβ sig-
naling are ALK5 kinase inhibitors. Several have been de-
scribed including EW-7195, EW-7203, EW-7197, IN-
1130, SB-431542, SD-208, SD-093, Ki26894, LY580276,
LY-573636, LY-2109761, and LY2152799 (see Table 1)
[78,79]. Each are novel small molecule inhibitors of ALK5
kinase (or TGFβ type 1 receptor kinase), required for
TGFβ 1 signaling.
TGFβ ligand binds to type 1 and type II receptor kinases
on the cell surface bringing them together allowing for
phosphorylation of receptor 1 kinase. Following phos-
phorylation, signaling proceeds in the cell through Smad
proteins (a total of at least 8 unique Smad proteins) ultim-
ately translocating to the nucleus and regulating the expres-
sion of target genes [80]. Blocking the receptor kinase at
the cell surface is an attractive target for drug development
and has shown promise in blocking EMT for therapeutic
benefit [81].
The potential clinical applicability of EW-7195 was
seen in preventing TGF1-β-dependent breast tumor me-
tastasis to the lung. EW-7195 inhibited both TGFβ in-
duced EMT and cell motility in vitro while inhibiting
lung metastasis in vivo [82]. EW-7203, IN-1130, and
EW-7197 were developed by the same group and dem-
onstrate a similar function in halting the TGF1β-
dependent EMT and also inhibiting metastatic spread
of primary tumor (breast to lung) [82].
SB-431542 is another small molecule inhibitor exert-
ing its affect through a highly specific interaction with
ALK5 kinase. SB-431542 competitively inhibits binding to
the ATP site of ALK5 kinase preventing downstream
activation of TGFβ targets. It does not act on other
kinase-dependent pathways including ERK, JNK, or p38
[83]. In a human glioma cell model, SB-431542 was able
to reduce cell proliferation and motility by repressing the
expression of EMT proteins [84]. Despite this promising
data, SB-431542, developed by GlaxoSmithKline (GSK),
has not made the transition to the clinical setting. Building
on the work with SB-431542, an orally available small mo-
lecular inhibitor with similar mechanism of action, GW-
788388 is currently being studied. GW-788388 has shown
promise for application in halting the progression of renal
fibrosis by inhibiting EMT [85]. Interestingly, GW-788388
also shows potential as a treatment for reversing cardiac
fibrosis in patients with Chagas disease [86].SD-208 and SD-093 are two additional small-molecule
inhibitors which target TGFβ-dependent EMT. SD-
208, an orally bioavailable compound, was noted to in-
hibit the development of pulmonary fibrosis in a rat model.
Subsequently, SD-208 was used in vivo in mouse metastatic
breast cancer models. SD-208 conferred a strong anti-
tumor effect in treated mice with no obvious signs of tox-
icity. SD-208 remains in the pre-clinical phase at this time,
however these data support a move to clinical trial in the
near future [87].
More selective small molecule inhibitors targeting
ALK5 kinase with specific activity towards either Smad
or non-Smad pathways have also been studied for their
ability to reverse or halt EMT in cancer progression.
The ALK5 inhibitor A-83-01 appears to inhibit Smad
signaling with little effect on non-canonical pathways.
Similar to the other ALK5 small molecule inhibitors, A-
83-01 demonstrates the ability to decrease expression of
EMT markers in a TGFβ-dependent fashion. A-83-01 not-
ably showed significantly more potency than other similar
small molecule inhibitors. [88].
Another TGFβ small molecule inhibitor, LY2157299,
has gained attention as a possible adjunctive treatment
for chemotherapy resistant cancers. In the case of triple
negative breast cancer, many are initially responsive to
traditional chemotherapeutic agents; however, the likeli-
hood of recurrence is high, typically with a more aggres-
sive, less responsive tumor. One hypothesis for this
pattern of disease is the resistance of a small population
of cells within the initial tumor to traditional chemother-
apy agents. This specialized group of cells, often de-
scribed as being cancer stem cells, relies on mechanisms
involving EMT to continue to survive [52].
Based on this background, LY2157299 (TGFβ kinase
antagonist) was used to treat a population of triple nega-
tive breast cancer cells previously treated with the che-
motherapeutic agent paclitaxel. LY2157299 treatment
reduced the size of paclitaxel-resistant cells, slowed the
growth rate of tumors, and reduced the tumor forming
potential of residual cancer cells [89].
LY2157299, currently in the Lily Oncology pipeline, is
being studied in clinical trial for application in myelo-
dysplastic syndromes (phase 2/3), hepatocellular carcin-
oma (phase 2), unresectable pancreatic cancer (phase
1b/2), and malignant glioma (phase 1b/2a). The progres-
sion of LY2157299 into a potential clinical therapeutic
highlights the potential of using small molecule inhibi-
tors that target EMT to treat advances malignancies.
2. Exogenous compounds
Several exogenous compounds, including dietary and
herbal chemopreventative agents may act in a TGFβ-
dependent fashion to impair EMT. Resveratrol is a nat-
ural polyphenol found most commonly in grapes and
red wine. It has been discussed in the oncology literature
Table 1 Small molecule inhibitors, mechanism, clinical targets, delivery, and status in clinical application
Inhibitors Mechanism Target Delivery Clinical status
CX-4945 CK2 inhibitor Lung, myeloma Oral, IV Phase 1/2
EW-7195 TGFβ Inhibitor Breast, Lung metastases Orally available Phase 1 Clinical Trial
EW-7203 TGFβ 1 and 2 receptor kinase inhibitor Breast, Lung metastases IV Pre-Clinical
EW-7197 TGFβ 1 and 2 receptor kinase inhibitor Breast, Lung metastases IV Pre-Clinical
IN-1130 TGFβ 1 and 2 receptor kinase inhibitor Breast, Lung metastases IV Pre-Clinical
SB-431542 Inhibition of ATP binding to ALK5 kinase Glioma IV Pre-Clinical
SD-208 TGFβ 1 receptor kinase inhibitor Metastatic breast cancer IV Pre-Clinical
SD-093 TGFβ 1 receptor kinase inhibitor Metastatic breast cancer IV Pre-Clinical
LY-2152799 TGFβ 1 receptor kinase antagonist Breast, Myelodysplastic syndromes,
Hepatocellular Carcinoma, Pancreatic
Cancer, Malignant Glioma
Orally available Clinical trial: Phase 2/3; Phase 2;
Phase 1b/2; Phase 1b/2a
LGK974 Porcupine inhibitor (Wnt signaling) Breast Orally available Phase 1 Clinical Trial
CWP232291 Wnt signaling inhibitor Hematologic malignancies (AML) Oral, IV Phase 1 Clinical Trial
MK-0752 ϒ-secretase inhibitor Cranial tumors, solid tumors Oral, IV Phase 1/2 Clinical Trial
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tasis and invasion [90,91]. Many mechanisms have been
suggested for its mode of action, however compelling
data suggest resveratrol may inhibit EMT. In a lung can-
cer model (A549 cells), treatment with TGFβ alone
compared with TGFβ and resveratrol showed no initi-
ation of EMT in the latter group. Cells treated with res-
veratrol increased expression of epithelial markers while
repressing fibronectin and vimentin. The mechanism ap-
peared to rely on modulating EMT transcription factors
SNAIL1 and SLUG [92].
Another dietary agent EGCG, the major polyphenolic
compound in green tea, demonstrates anti-proliferative ef-
fects in several cancers [93]. EGCG inhibits the induction
of p300/CBP, a histone acetyltransferase with known activ-
ity on Smad2 and Smad3. In lung cancer cells treated with
EGCG, TGFβ induction of EMT was potently halted in a
Smad2/Smad3-dependent fashion. EGCG, acting through
p300/CBP was able to prevent EMT and blocked invasion
of lung cancer cells [94].
The translation of bench findings to clinical trial for
both resveratrol and EGCG has been challenging. At this
stage, resveratrol has been studied in phase 1 clinical trial
and EGCG remains in pre-clinical study. Other dietary
and herbal chemopreventative agents also have been noted
to inhibit EMT through non-TGFβ-dependent mecha-
nisms. β-elemene, an active component of the herbal
medicine Curcuma wenyujin, acts to stop EMT through
Smad3 [95].
Curcumin, the active component of the spice turmeric, is
an inhibitor of EMT by altering the SNAIL1 transcription
factor [12]. 2-Hydroxycinnamaldehyde also inhibits EMT
via a SNAIL-dependent mechanism in breast cancer cells
and also prevents lung metastasis in a mouse orthotopic
breast cancer model [96]. The next steps for each isdevising the best mode of drug delivery, further drug
development, and devising treatments to synergize
with existing cancer therapeutics.
Non-coding RNAs Studying miRNAs and their po-
tential role in cancer is an extremely fast-growing area
of research. In parallel, several research groups are
working on ways to modulate the effect of miRNAs
in tumor biology with the intent of developing new
and novel therapeutic targets. Antagomirs and miRNA
sponges each show promise for future clinical appli-
cation and will be discussed.
1. Antagomirs
As described earlier, miRNAs can play a role in cancer
progression and metastases leading to them often being
referred to as “onco-miRs” [97]. Antagomirs were first
described and designed by Krϋtzfeldt et al. in 2005. They
were developed as pharmacologic agents to silence miR-
NAs in vivo and defined as being single-stranded RNAs
complementary to miRNAs. Krϋtzfeldt’s group demon-
strated antagomir-122, selective against miR-122,
completely silenced its target in multiple tissues types
[98]. Similar findings were seen with other antagomirs
showing a broad bioavailability and potent effect across
tissue types.
The same group responsible for determining the im-
portant role played by miR-10b in breast cancer invasion
and metastatic progression also utilized an antagomir
(antagomir-10b) to silence miR-10b in vitro and in vivo.
Interestingly, antagomir-10b did not reduce the bulk or
size of the primary mammary tumor. However, it signifi-
cantly suppressed the formation of metastatic lesions in
a mouse. Overall it was well tolerated by treated animals
laying the groundwork for further study of antagomirs
as anti-cancer drugs [51,99].
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miRNA sponges are another tool increasingly utilized
to modify the activity of miRNAs [100]. These sponges
are constructed by utilizing 3’UTR mRNA sites comple-
mentary to targeted miRNA. By doing so, they act as a
binding site for specific miRNAs and functionally inhibit
miRNA binding to native targets [101]. Early work dem-
onstrates that miRNA sponges can down-regulate
tumorigenic miRNAs in vivo [102]. The important ques-
tion that remains to be answered is how well this strat-
egy would work as a cancer therapy and if it would be
tolerated by patients.
As illustrated, this remains a relatively young area of
work with few advancements to the clinical setting to
date. However, strategies including the development of
antagomirs and miRNA sponges have the potential to make
an impact on a patient level.
Cancer stem cells As discussed, EMT signaling path-
ways have important roles in the transformation of
epithelial cells into CSCs. Several groups have started
the process towards drug development to inhibit this
process using large-scale screening techniques [103,104].
The results of these screens allows for the identification
of potential pharmacologic agents for eliminating CSCs.
Understanding the properties of these agents and asses-
sing their biologic activity is the first step towards drug
development as stand-alone agents or as adjunctive
therapies [103].
Another strategy for eliminating CSCs is specifically
targeting EMT pathways important for their generation
and maintenance. Physiologic factors already exist to
prevent mesenchymal transition, likely secreted by epi-
thelial cells in order to remain in a fixed state. These
autocrine factors include Dickkopf-1 (DKK1) and secreted
frizzle-related protein 1 (SFRP1), both known inhibitors
of Wnt pathways. These proteins could be pharmaco-
logically mimicked to produce a similar effect in dis-
eased states [105].
1. Small molecule inhibitors
Wnt pathway inhibitors currently in development
for the purpose of inhibiting CSC formation include
LGK974 and CWP232291 (see Table 1). LGK974 is a
small molecule inhibitor of Porcupine, a Wnt-specific
acyltransferase, and strongly inhibits Wnt signaling both
in vitro and in vivo. In rodent breast cancer models,
LGK974 demonstrated dose dependent tumor regression
with acceptable tolerance and oral bioavailability [106].
LGK974 is presently in phase 1 clinical trial. CWP232291
is another small molecule Wnt pathway inhibitor which
notably produced marked cytotoxicity against CSCs in
hematologic malignancies while showing minimal effect
on normal bone marrow cells. These findings led to its ap-
plication for treating AML. CWP232291 is currently inrecruitment for a phase 1 clinical trial for treatment of re-
lapsed or recurrent AML [107].
Notch signaling has also been targeted with small mol-
ecule inhibitors, both as independent and adjunctive
therapies. MK-0752 is a potent γ-secretase inhibitor with
strong efficacy for regulating Notch signaling, particularly
in cells with stem-like properties. MK-0752 is also orally
available making it an attractive potential chemotherapeu-
tic. Phase 1 studies show acceptable tolerability, however
low efficacy as a single treatment for extra-cranial tumors
[108]. MK-0752 is presently in clinical trial assessing its
potential for use in multidrug regimens for advanced solid
tumors.
2. Metformin
Small molecule inhibitors offer the potential for future
therapeutic options against difficult to treat malignan-
cies, particularly those which demonstrate treatment re-
sistance. The transition from the bench to wide-spread
use, however, is often long and difficult. Utilizing
pharmacologic agents already used in clinical practice to
target CSCs would have the potential to more quickly
impact patients. Recent work with the oral hypoglycemic
metformin offers a possible model to follow for applying
this strategy. Metformin, a mainstay in contemporary
management of type 2 diabetes mellitus, is extremely well
tolerated and extensively used. The link between cancer
and metformin was first reported in 2005 after studying a
large group of patients using a national database [109].
Based on this observation, several groups tested the
biologic impact of metformin on tumor progression in
mice models. Interestingly, metformin can inhibit the
growth of solid tumors, including breast tumors, in both
diabetic and non-diabetic mice [110,111]. Several mech-
anisms have been proposed to explain this result, how-
ever it appears that metformin can selectively inhibit the
growth of breast CSCs by modifying the EMT machin-
ery [112]. When combined with conventional chemo-
therapeutics, the effect is potentiated [113]. This is an
important example of leveraging existing therapies to
modify EMTs. Additional EMT pathway targets and
novel pharmacologic agents targeting CSCs are well-
summarized in another recent review [114].
Altering the tumor microenvironment
To this point, EMT has largely been discussed as a process
at the tumor level, with the transition to a mesenchymal
phenotype occurring in tightly regulated fashion. Inducers
of EMT come from many sources including the tissue
environment in which the cell originates. With travel to
distant sites, as is the case in metastatic disease, a new
microenvironment in encountered. Clearly, the interplay
between the tumor microenvironment (TMEN) and the
tumor – including the microenvironment as a stimulator
of EMTs – is important in cancer progression [115].
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to direct therapies to prevent EMT.
Components of the TMEN The TMEN is a specialized
extracellular matrix (ECM) wherein a cancer cell prolifer-
ates [116]. The components, therefore, are similar to those
seen in any inflammatory ECM and include soluble factors,
cytokines, chemokines, neovascular elements, immune
cells, and mesenchymal stem cells (and their derivatives)
[117,118] Within the microenvironment, several compo-
nents are clearly cancer-promoting elements [119].
The cytokines IL-1, IL-8, IL-10, and TGFβ all demon-
strate effects on either tumor growth or metastasis through
their interactions with cancer cells. The major cell types re-
sponsible for these mediators in the TMEN include the pri-
mary tumor cell and stromal cells including macrophages,
adipocytes, and cancer associated fibroblasts (CAFs) [118].
A key cell type in the TMEN are mesenchymal stem cells
(MSCs) which exhibit the ability to differentiate into nearly
all stromal cell lineages. The plasticity of MSCs and their
importance in maintaining the TMEN make them a critical
target in cancer therapy [120].
Microenvironmental regulators of EMT Mesenchymal
stem cells (MSCs) have the ability to induce EMTs in several
models and play a role in both pre-metastatic and metastatic
sites. Breast cancer cell lines (MDA-MB-231, T47D, SK-Br3)
cultured with MSCs increase expression of EMT markers
(N-cadherin, Vimentin, Twist, SNAIL) with concomitant
decrease in E-cadherin expression. This increase in EMT
markers corresponded with an increase in protein expres-
sion as well, with increased Vimentin and SNAIL com-
pared to untreated cells. Gene expression assays also
revealed upregulation of TGFβ-receptor implicating TGFβ
mechanistically as a regulator of this EMT. This occurred
with only co-culturing these breast cancer cell lines with
MSCs and no further co-stimulatory factors [121].
A similar role for MSCs initiating EMT is seen in hepa-
tocellular carcinoma (HCC). HCC cell lines (SMMC-7721
and Hep-3B) expressed EMT markers after exposure to
IFNy and TNF-alpha stimulated MSCs. The mechanism
of action appeared to be via TGFβ expressed by MSCs,
similar to results seen in breast cancer cell lines. These
findings were correlated to clinical samples revealing
over-expression of SSEA-4 (a marker for MSCs in clinical
HCC tissues) was found to confer a shorter cancer-free
interval and worse overall survival [122].
While MSCs have the ability to initiate EMTs, they
also differentiate into other cell types within the TMEN to
potentiate their action as tumor promoters. One particular
cell type, the cancer-associated fibroblast (CAF) has gar-
nered significant attention as a target for cancer therapy
[123]. CAFs are defined by their similarities with myofi-
broblasts based on their origin (bone marrow or by EMTof resident fibroblasts) and pattern of surface expression
(most notably alpha-SMA, MMP1, MMP3) [124]. Unlike
myofibroblasts, CAFs are not removed by apoptosis and
cannot be “deactivated”. Given that CAFs are the most
abundant cell type in the TMEN in several cancers
(breast, prostate, pancreatic), that they can stimulate EMT,
and they are important mediators of chemotherapy resist-
ance, eliminating CAFs offers an exciting drug target.
Therapeutic targets of TMEN-stimulated EMTs The
most significant challenge of designing therapies to
eliminate CAFs are their similarities with myofibroblasts –
which are essential for wound healing. Predictably, the
pathways used in cancer progression are also essential
for wound healing [125]. Osteopontin, a secreted
phosphoprotein implicated in tumor metastasis both
mechanistically and as a marker, is able to induce
MSCs to adopt a CAF phenotype through autocrine
signaling of TGFβ-1 [126]. This pathway, first observed in
breast cancer, was also noted to be conserved in bone
fracture healing (unpublished data). Unlike in cancer,
where this signaling pathway is pathologic, fracture
healing is dependent on the differentiation of MSCs into
myofibroblasts to ensure appropriate bone remodeling.
Cancer drugs must be specific to CAFs without nega-
tively affecting myofibroblasts or other cell lines import-
ant for healing.
Despite these inherent challenges, strategies to inhibit
CAFs have been tried at numerous potential points of
intervention. Imatinib mesylate, a tyrosine kinase inhibitor
currently used in the clinical setting for treatment of
numerous malignancies, decreased the viability of CAFs
in vitro by inhibiting expression of alpha-SMA [127].
Another approach targeting TGFβ uses the antisense
oligonucleotide AP-12009 for the treatment of glioma
[128]. At present, AP-12009 (Trabedersen) is being pre-
pared to be tested in a phase II clinical trial for systemic
IV administration in malignant melanoma and pancre-
atic cancer.
Another potential site for intervention within the TMEN
include blocking the interaction between MSCs and cancer
cells by preventing MSC recruitment to tumor sites.
Zoledronic acid (ZA), a bisphosphonate, appears to
show promise in this role. Specifically, in a breast cancer
model, treatment with ZA prevented MSC migration
by decreasing the expression of RANTES and IL-6,
both markers for MSC migration. These data suggest a
role for ZA as an adjunctive therapy to conventional
chemotherapeutics [129].
Conclusions
EMT plays a considerable role both in normal develop-
ment and diseased states. Understanding the interplay
between EMT and development, both embryologically
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in determining the key regulatory steps for progression
to disease. Shared molecular pathways amongst all EMTs
allows for the development of novel therapies to potentially
halt or reverse EMT prior to metastatic spread. Small
molecule inhibitors and exogenous compounds appear
to offer the most promise at this stage.
Additionally, the interplay between the TMEN and
induction of EMT creates yet another opportunity to
design targeted therapies in cancer. Modulating the
key effectors within the tumor stroma is an area ripe
for drug development. Undoubtedly, EMTs and their
regulators have significant clinical implication across
the oncologic spectrum.
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